Jade Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its current pipeline centers on antibody-based programs designed to target key immune pathways involved in conditions such as immunoglobulin A nephropathy and other inflammation-related disorders. The company’s lead candidate, JADE101, is being developed to inhibit APRIL, a protein linked to abnormal immune activity, while JADE201 and JADE301 are advancing through earlier-stage research for additional autoimmune indications. Jade Biosciences works as a development-focused biopharmaceutical company, relying on clinical research, preclinical testing, and collaboration agreements to advance its programs. Headquartered in Waltham, Massachusetts, the company serves the immunology and nephrology fields by pursuing targeted biologic therapies for patients with significant unmet medical needs.
WebsiteBuilding 23
Waltham, MA, 02453
United States
Investors talking about AVTE also mention
What share of all stock conversation is about AVTE?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% new | 0% 0 |
Of the messages about AVTE that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | — | 5% -88.24 | ||
| Bearish | — | — | — | 95% +88.24 |
Of the messages about AVTE that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 100% | 71.43% | 75% | ||
| Controversies | — | 0% | 28.57% | 25% | ||
| Analysts | — | 0% | 0% | 0% | ||
| Earnings | — | 0% | 0% | 0% | ||
| Macro | — | 0% | 0% | 0% | ||
| Technical Analysis | — | 0% | 0% | 0% |
Of the messages about AVTE, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | 0% | 40% | 29.27% | ||
| Newcomers | — | 100% | 60% | 70.73% |